



iKnowMed July 2026 Release Preview



iKnowMed July 2026 | Release Highlights

Strengthen Control & Compliance

Help reduce claim denials, minimize rework, and support more accurate reimbursement

- Aligns ICD-10 sequencing to primary diagnosis for more compliant claims
- Improves administration coding for IV Push medications
- Adds billing context to printed orders



Simplify Everyday Workflows

Reduces manual steps, saves time for staff, and streamlines order processing

- Brings billing visibility directly into printed orders and the Orders Queue
- Enables medication order printing from the Orders Queue
- Adds CPT-based search for faster regimen setup



Drive Revenue Accuracy

Supports cleaner system configuration, better decision visibility, and alignment with regulatory and clinical standards

- Enhances Therapeutic Interchange management and visibility
- Aligns care plan documentation with MIPS requirements
- Updates precision medicine panels to reflect current testing options
- Improves user access visibility with Okta-aligned administration



Therapeutic Interchange: Enhancements

July 2026 Release

What's Changing?

Therapeutic Interchange (TIC) updates improve how you manage preferred entries and payer rules, including:

- The ability to delete unused configurations
- Clearer edit controls based on effective dates
- Increased visibility into override decisions.

Why?

- These updates make it easier to keep TIC configurations clean and accurate while protecting rules already in use.
- Added visibility into override reasons and comments improves transparency across clinical, ordering, and financial workflows.

Therapeutic Interchange: Delete practice preferred entries and payer rules

Manage Preferred Medication

Medication Name *
Trastuzumab-anns IV

Product Code
Select a Product Code

From * 06/26/2026 To mm/dd/yyyy

Reason
Select reason

Comments
Type something

Max 4,000 Characters

+ ADD NEW

CANCEL SAVE

Therapeutic Interchange > trastuzumab-Herceptin

NEW PAYER RULE MANAGE PREFERRED [P]

	Medication Name	Preferred Effective Date	Medication Status	Last Modified By
>	Trastuzumab IV	--	Active	Cvpphn1, Cvpphfn1
>	Trastuzumab-anns IV	--	Active	qa2, Hariharan
>	Trastuzumab-dkst IV	04/17/2026 to 04/18/2026	Active	qa2, Hariharan
>	Trastuzumab-dttb IV	04/15/2026 to 04/16/2026	Active	qa2, Hariharan
>	Trastuzumab-pkrib IV	--	Active	--
▼	Trastuzumab-qyyp IV	--	Active	qa2, Hariharan

Payer ID	Effective Date	Reason	Comments	DELETE
123 MNJ CRCOMECX E TEST	05/20/2026 to 05/20/2026	Drug Availability	--	

< 1 >

Therapeutic Interchange: Restricted editing for TIC payer rules based on From date

From Date in the Future

Editable: From date, To date, Payer ID, Reason, Comments

✕

Medication Name *

Denosumab Subcutaneous (120 mg/1.7 mL - X... ▼

Payer ID * Required

2 Selected ▼

From * To

07/15/2026  08/14/2026 

Reason

Practice Preferred ▼

Comments

Type something

Maximum 4,000 Characters

CANCEL

SAVE

From Date in the Past

Locked: From date and Payer ID

✕

Medication Name *

Denosumab Subcutaneous (120 mg/1.7 mL - X... ▼

Payer ID * Required

1 Selected ▼

From * To

06/26/2026  mm/dd/yyyy 

Reason

Select reason ▼

Comments

Type something

Maximum 4,000 Characters

CANCEL

SAVE

ontada[®]
By McKesson

© 2026 Confidential and proprietary

5

Therapeutic Interchange: Override comments visible on OTIC hover

Ordering Regimen

user1phy1's Dashboard
Therapeutic Interchange ✕
Test 17938 (56 / M) ✕

>
Test 17938 (56 / M)

DOB: 05/14/1970
MRN: Test17938
Attending: -
Dx: Colon cancer
Ht/Wt/BSA: 66

Chart Summary
Clinical Profile
Flowsheet
 Orders
Results
Documents
Dx

New Orders (0)
 Medications (0)
Regimens (11)
 Order Review
 Order History
 Drafts

Pegfilgrastim Products

Additional Medications	Add an Order	Search Orderables
☐ Udenyca (Pegfilgrastim-cbqv Subcutaneous) Udenyca (Pegfilgrastim-cbqv Subcutaneous) 6 mg/0.6 mL syringe 6 mg subcutaneously once. Instructions: Administer once per cycle at least 24 hours after chemotherapy. NOTE:		
☐ Udenyca Onbody (pegfilgrastim-cbqv Subcutaneous (via wearable injector)) Udenyca Onbody (pegfilgrastim-cbqv Subcutaneous (via wearable injector)) 6 mg/0.6 mL syringe, w/ wearable injec 6 mg subcutaneously using wearable injector once. Instructions: May be applied by a healthcare professional on chemotherapy in a multi-day regimen using only the co-packaged pegfilgrastim. Usually applied to the abdomen, th caregiver available to monitor the injector. Pegfilgrastim will begin infusing approximately 27 hours later and deliver Udenyca On Body Injector.		
☐ Udenyca (Pegfilgrastim-cbqv Subcutaneous Auto-Injector) Udenyca (Pegfilgrastim-cbqv Subcutaneous Auto-Injector) 6 mg/0.6 mL auto-injector 6 mg subcutaneously As Directed. Administer 24 hours after chemotherapy. See Instructions for Use. NOTE: This is Dispense: 1 Each Refills: 0 Allow Substitution		
☐ Stimufend (Pegfilgrastim-fpgk Subcutaneous) Stimufend (Pegfilgrastim-fpgk Subcutaneous) 6 mg/0.6 mL syringe 6 mg subcutaneously once. Instructions: Administer once per cycle at least 24 hours after chemotherapy. NOTE:		
TIC ☒ Nyvepria (Pegfilgrastim-apgf Subcutaneous) Nyvepria (Pegfilgrastim-apgf Subcutaneous) 6 mg/0.6 mL syringe 6 mg subcutaneously once. Instructions: Administer once per cycle at least 24 hours after chemotherapy. NOTE: Product Code: J3939431		
OTC ☒ Fulphila (Pegfilgrastim-jmdb Subcutaneous) Fulphila (Pegfilgrastim-jmdb Subcutaneous) 6 mg/0.6 mL syringe Instructions: Administer once per cycle at least 24 hours after chemotherapy. NOTE:		
Practice Preferred Override by: user1phy1 phy on 05/14/2026 Reason: Patient Preference Comments: Override Comments test ☐ Pegfilgrastim Subcutaneous (via wearable injector) Pegfilgrastim Subcutaneous (via wearable injector) 6 mg/0.6 mL syringe, w/ wearable injector 6 mg subcutaneously using wearable injector once. Instructions: May be applied by a healthcare professional on chemotherapy in a multi-day regimen using only the co-packaged pegfilgrastim. Within 3 minutes of filling the On-bo patient's skin (abdomen or back of arm). Usually applied to the abdomen, the back of arm should only be used if the Pegfilgrastim will begin infusing approximately 27 hours later and deliver pegfilgrastim over 45 minutes. NOTE: Thi		
☐ Rolveodon (Elaepegrestin-xnst Subcutaneous) Rolveodon (Elaepegrestin-xnst Subcutaneous) 13.2 mg/0.6 mL syringe 13.2 mg subcutaneously once. Instructions: Administer once per cycle at least 24 hours after and 14 days before		
☐ Ryzneuta (efbemelengrastim alfa-vuxw Subcutaneous) Ryzneuta (efbemelengrastim alfa-vuxw Subcutaneous) 20 mg/mL syringe 20 mg subcutaneously once. Instructions: Administer once per cycle at least 24 hours after and 14 days before		

Orders Queue

← → ↻ 📄 g2qa2.mckesson.com/ehr/app.jsp

iKnowMed™ Generation 2 🔍 Search Patient Name or ID ⌂ 📅 Doc View of MPRT San Francisco Medical Oncology - 05/14/2026 Worklist Queue

user1phy1's Dashboard Therapeutic Interchange Test 17938 (S6 / M) Worklist Queues

Sign Orders Admin Attach Documents Outbound Fax Ins. Auth/Fin. Counseling Oncology Care Model OCM Patient List **Orders Queue**

Search Patient Name or ID 🔍

FILTERS 1 Patients ⓘ

> Filter Presets Custom

Sort By Order Date (Oldest to Newest)

Patient Information	Date
17938, Test (M) MRN: Test17938 DOB: 05/14/1970 (56) Orders: Fulphila (Pegfilgrastim-jndb Subcutaneous), Nyvepria (Pegfilgrastim-apgf Subcutaneous)	05/14/2026

MESSAGE

Phone:
Address:
Email:
Problem(s): Colon cancer
Insurance:
Attending:
Allergies: NKA
Next MD Visit:

Group By Order Date (Oldest to Newest)

Show all from past 13 months

Thursday, May 14, 2026

Order Details
Fulphila (Pegfilgrastim-jndb Subcutaneous) Nyvepria (Pegfilgrastim-apgf Subcutaneous)

PREVIOUS NEXT Select All Orders Select Labs

Update Selected Orders:

Location Type	Perform Location	Perform Date	Qty
Select Option	Select Option	MM/DD/YYYY	

Use My Logged-in Location

Thursday, May 14, 2026

Practice Preferred
Override by: user1phy1 on 05/14/2026
Reason: Patient Preference
Comments: Override Comments test
Pegfilgrastim Products (ADDITIONAL MEDICATIONS) ⓘ

Dose Form: 6 mg/0.6 mL syringe

Sig: 6 mg subcutaneously once. Instructions: Administer once per cycle at least 24 hours after chemotherapy. NOTE: This is Fulphila.

Associated Problem: Colon cancer *

Ordered/Edited By: Phy, User1phy1 on 05/14/2026

Order Instructions: Administer once per cycle at least 24 hours after and 14 days before chemotherapy. NOTE: This is Fulphila.

TC

Nyvepria (Pegfilgrastim-apgf Subcutaneous)
Pegfilgrastim Products (ADDITIONAL MEDICATIONS) ⓘ

Dose Form: 6 mg/0.6 mL syringe

Therapeutic Interchange: Override comments visible on OTIC hover

Ins. Auth/Fin. Counseling

g2qa2.mckesson.com/ehr/app.jsp

iKnowMed™ Generation 2

Search Patient Name or ID

user1phy1's Dashboard Therapeutic Interchange Test 17938 (56 / M) Worklist Queues

Imaging Other Documents Notes Review Sign Orders Admix Attach Documents Outbound Fax Ins. Auth/Fin. Counseling

Filter Criteria

For faster results, select a short date range and one status

Patient: Search Patient Name or ID

Ordered Date: Next 2 weeks

Planned Start Date: Next 2 weeks

Business Office Status:

☐ Obtained ☐ Not needed

☒ Not obtained ☐ Declined

☐ Off label ☐ Pending

☐ Archived

More Filters ...

Reset APPLY FILTERS

Patient (DOB-MRN)	Order	Physician	Start Date	Status	Order Modify Date
17938, Test (05/14/1970 - Test17938)	Pegfilgrastim Products	phy. user1phy1	05/15/2026	Not obtained	05/14/2026
Demo, IKM (03/08/1963 - 79879)	Hydrocortisone IV 15 mg	QA2, CMM	05/14/2026	Not obtained	05/14/2026
Demo, IKM (03/08/1963 - 79879)	Atropine IV 0.4 mg	QA2, CMM	05/14/2026	Not obtained	05/14/2026
Demo, IKM (03/08/1963 - 79879)	Atropine IV 0.4 mg	QA2, CMM	05/14/2026	Not obtained	05/14/2026
17642, Test (03/23/1980 - Test17642)	Pegfilgrastim Products	Cvpphin1, Cvpphin1	05/15/2026	Not obtained	05/14/2026
Chugaswme, Uzuggpugdz (06/15/1972 - D6XA5GY55581YF)	Paclitaxel IV 114 mg(80 mg/m2)	Cvpphin1, Cvpphin1	05/14/2026	Not obtained	05/14/2026
Chugaswme, Uzuggpugdz (06/15/1972 - D6XA5GY55581YF)	Famotidine IV 20 mg	Cvpphin1, Cvpphin1	05/14/2026	Not obtained	05/14/2026
Kpfuyoxaqe, Nachkim (01/24/1967 - YQA748M7TTYQEM)	Famotidine IV 20 mg	Cvpphin1, Cvpphin1	05/14/2026	Not obtained	05/14/2026
Kpfuyoxaqe, Nachkim (01/24/1967 - YQA748M7TTYQEM)	Claplatin IV 70 mg(50 mg/m2)	Cvpphin1, Cvpphin1	05/14/2026	Not obtained	05/14/2026
Aoczbisfq, Kdpeus (07/16/2000 - MW6AJ92H5H0Q)	Famotidine IV 20 mg	Cvpphin1, Cvpphin1	05/14/2026	Not obtained	05/14/2026

1-13 of 741

GO TO CHART

Regimen: Pegfilgrastim Products
Number of Cycles: 1 Cycle Length: 14
Prim. Ins.:
Diagnosis/Problem: Colon cancer
ICD10: Not Documented
LOT: 1st Line Metastatic or Recurrent

Planned Start Date: 05/14/2026
Insurance Start Date:

Business Office Status:

Obtained: 0

Select Authorization: New Authorization

☐ Pending

☐ Obtained

☒ Not obtained

☐ Off label

☐ Not needed

☐ Declined

Status: Not obtained

Insurance: Selected

Reference #: Contact:

Current Payer Decision

No decision from Payer yet.

Notes:

Initial Regimen Orders

Practice Preferred

Override by: user1phy1 phy on 05/14/2026

Reason: Patient Preference

Comments: Override Comments test

onc. Fuphris (Pegfilgrastim-jmd) Subcutaneous) 6 mg/0.6 mL syringe 6 mg subcutaneously once. Instructions: Administer once per cycle

Orders: Billing designation on printed non-medication orders

July 2026 Release

What's Changing?

- Billing designations (Insurance, Research, Do Not Bill) selected for non-medication orders will now appear on printed orders.

Why?

- Provides clear billing context at the point of fulfillment
- Eliminating guesswork and reducing the need for follow-up to determine how an order should be processed.

Orders: Billing designation on printed non-medication orders

CXR

* required

Options for Occurrence

• Edit order

• Move Order

• Print

• Fax

• Renew Order

• Discontinue (D/C)

• Audit History

Perform Date

06/30/2026

Details

CXR

Associated Problem(s): Acute myeloid leukemia * (C92.01)

Bill: Research

Perform Location: SC Cancer Clinic Test

CLOSE

Orders Queue: Billing designations + medication order printing

July 2026 Release

What's Changing?

- Printed orders from the Orders Queue will now include billing designations for both medication and non-medication orders.
- Medication orders can now be printed directly from the queue.

Why?

- Teams working in the Orders Queue will have complete billing visibility and can print what they need without navigating elsewhere, streamlining fulfillment workflows and saving time.

Orders Queue: Billing designations + medication order printing

Mylocation Austin Oncology
26428 Nicole Cliff
Grannis AR - 71944
Phone: 0821603627

ATTENTION: This report may contain Protected Health Information as defined by HIPAA and should be managed in accordance with your organization's policies for Protected Health Information.

Patient: Mebxvpg, Umwuhmz
MRN: CJA91A0V7Y5R348

DOB: 02/01/2000
Sex: Female

Location Name: Mylocation Austin Oncology
Location Address: 26428 Nicole Cliff,
Grannis AR - 71944
Location Phone: 0821603627
Location Fax :

Allergies:

Not Documented

Imaging

Order: MRI
To Be Performed: Prior to Next Visit
Associated Problem(s): **Acute myeloid leukemia * (C92.00)**
Order Instructions:

Order Date: 06/26/2026
Perform Location:

Billing: Insurance

Charge Capture Report: ICD-10 sequencing by primary diagnosis

July 2026 Release

What's Changing?

- ICD-10 codes will now be ordered based on primary diagnosis designation rather than strictly alphabetically.

Why?

- This ensures claims reflect the correct primary diagnosis, aligning with payer expectations and reducing the risk of denials, rework, and incorrect reimbursement.

Charge Capture Report: ICD-10 sequencing by primary diagnosis

Charge Capture Report

05/29/2026

▶ REFRESH

MRN: May29Pat2Test

Practice: Onc Hem of MSH

Seen By:

Location: Fremont

RELEASE DRUG CODES

Status: Released

Captured Charges

Code	Count	Description	ICD	NDC	Comments
96523	1	IRRIGAJ IMPLNTD VENOUS ACCESS DRUG DELIVERY SYST	I10,F41.0		

D/W = Dispensed/Wasted

Medication Administration Detail

* The number of elapsed minutes between start and stop time minus any minutes when there was simultaneous administration with higher RVU's

Problem List

Problem	ICD10
Primary hypertension	I10
Anxiousness	F41.0
Smokes	
Tumescence	

Charge Capture Report: IV Push administration code correction

July 2026 Release

What's Changing?

- IV Push (IVP) drug administration codes will now be assigned based on duration, aligning with existing IV Piggyback logic.

Why?

- This improves billing accuracy by ensuring the correct administration codes are captured, reducing claim errors and the need for downstream corrections.

Charge Capture Report: IV Push administration code correction

Charge Capture Report

05/20/2026

▶

REFRESH



Code	Count	Description	ICD	NDC	Comments
96375	1	Therapeutic Push - Sequential			
96413	1	Chemo Infusion - Initial	Z51.11		
J2469	10	Palonosetron IV, 0.025 mg			D/W: 0.25/0 mg
J9000	9	Doxorubicin IV, 10 mg	Z51.11		D/W: 83/0 mg

D/W = Dispensed/Wasted

Medication Administration Detail

Start	Stop	Min.*	Drug	Waste	Route	Admin Code	Description
10:00 AM	10:10 AM	10	Palonosetron IV 0.25 mg	0 mg	Push	96375*1	Therapeutic Push - Sequential
10:20 AM	10:40 AM	20	Doxorubicin IV 83 mg	0 mg	Push	96413*1	Chemo Infusion - Initial

** The number of elapsed minutes between start and stop time minus any minutes when there was simultaneous administration with higher RVU's*

Problem List

Problem	ICD10
Colon cancer	



© 2026 Confidential and proprietary

15

Care Plan: Updated acute health crisis terminology

July 2026 Release

What's Changing?

- The medical reason option has been updated from **urgent or emergent medical situation** to **acute health crisis**.

Why?

- This change aligns documentation more precisely with MIPS-130 requirements, supporting accurate quality reporting for participating practices.

Care Plan: Updated acute health crisis terminology

Clinical Quality Exceptions (Date of service: 06/26/2026)

required

TODAY

Medical Reasons

Patient Reasons

▼ Breast Cancer/Combination Chemotherapy for Hormone Negative-Recommended Not Administered

Decision Date

TODAY

Medical Reasons

Patient Reasons

▼ Current Medication

Decision Date

TODAY

▼ Medical Reasons

☐ Patient is in an acute health crisis.

▼ Tobacco Use Cessation Counseling

Decision Date

TODAY

Medical Reasons

▼ Body Mass Index (BMI) Screening and Follow-Up Plan

Decision Date

TODAY

Medical Reasons

SAVE

CLOSE

Regimen Templates: Search for Non-Medication Orderables by CPT Code

July 2026 Release

What's Changing?

- Users can now search for non-medication orderables using CPT codes when building or editing regimen templates.

Why?

- This speeds up regimen configuration and reduces the risk of selecting incorrect items by eliminating the need to manually match CPT codes to orderable names.

Regimen Templates: Search for Non-Medication Orderables by CPT Code

Search/Add Orderables

Search:

☐ Medications ☒ Labs ☒ Imaging ☒ Services ☐ Supplies ☐ OrderSetDefs ☒ SupportiveCareRegimen

Search Results

Service (89)

Annual depression screening, 5 to 15 minutes(G0444)

Annual alcohol misuse screening, 5 to 15 minutes(G0442)

Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit(G0439)

Face-to-face behavioral counseling for obesity, 15 minutes(G0447)

Electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report(G0403)

Hepatitis c antibody screening, for individual at high risk and other covered indication(s)(G0472)

Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes(G0446)

Colorectal cancer screening; stool-based dna and fecal occult hemoglobin (e.g., kras, ndrg4 and bmp3)(G0464)

Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit(G0438)

Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment(G0402)

Hiv antigen/antibody, combination assay, screening(G0475)

Molecular pathology procedure; physician interpretation and report(G0452)

Electrocardiogram, routine ecg with 12 leads; interpretation and report only, performed as a screening for the initial preventive physical examination(G0405)

Brief face-to-face behavioral counseling for alcohol misuse, 15 minutes(G0443)

Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and followed by a neutralizing confirmatory test, when perfo(G0499)

Electrocardiogram, routine ecg with 12 leads; tracing only, without interpretation and report, performed as a screening for the initial preventive physical examination(G0404)

Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes(G0436)

Additional iKnowMed Updates

	What Changed	Why it Matters
1 Precision Medicine: Caris & Guardant Updates	Existing Caris and Guardant panels have been updated, and new Guardant panels have been added to the electronic ordering workflow.	Clinicians will have access to the latest testing options directly within iKnowMed, helping ensure ordering reflects current diagnostic and therapeutic capabilities.
2 Admin: User management updates	— The Admin > Users page has been updated to reflect Okta-based identity management, including new visibility into user status, access, and migration status. — Previously hidden users with revoked access will also be restored to view.	— Admins gain a clearer, more complete view of user access while avoiding conflicting account actions between iKnowMed and Okta. — This supports more consistent and secure user management.



New Unfinished Charting Dashboard

The new **Unfinished Charting dashboard** gives you a complete, exportable view of unfinished items across your practice, without the date restrictions of the in-app widget.

Use the new dashboard to:

- Track unfinished items such as charting, billing, notes, pain care plans, and orders by providers or patients
- Narrow results using location, provider, and unfinished item filters
- Generate reports to distribute as needed

July Release

iKnowMed Self-Service Reporting

Enhancements to be available Monday,
July 13, 2026

New Unfinished Charting Dashboard

Reports

Generated Reports

Practice Scheduled Reports

Reports > Unfinished Charting

RESET ALL

FILTER PREVIEW

Filter Preset
None Save New

Open All Collapse All

Date Of Appointment +1 >

LOCATION & PROVIDERS

Region >

Location >

Provider/User Type >

Providers >

UNFINISHED CHARTING ITEMS

Tasks >

Notes >

Pain Care Plan >

PREVIEW

GENERATE

Filter:

Clear

FILTER BY SELECTION

Providers

Resources	Patients with Unfinished Charting	Unfinished Notes	Unfinished Pain Care	Missing Billing Codes	Draft Orders
Cvpphln1, Cvpphfn1	54	45	54	52	0
cvp_g2qa1, cvp_g2qa1	2	2	2	2	0
Message, Disha	1	1	1	1	0
X789, SZG2QA	1	1	1	1	0
Bvoftamd, Xtrmndq	1	0	1	1	0
ksphy, anjali	1	1	1	1	0
Fillmore, Seth	1	1	1	1	0
Oeesnvx, Agmgcfd	1	0	1	1	0

Reports

Generated Reports

Practice Scheduled Reports

Reports > Unfinished Charting

RESET ALL

FILTER PREVIEW

Filter Preset
None Save New

Open All Collapse All

Date Of Appointment +1 >

LOCATION & PROVIDERS

Region >

Location >

Provider/User Type >

Providers >

UNFINISHED CHARTING ITEMS

Tasks >

Notes >

Pain Care Plan >

PREVIEW

GENERATE

Unfinished Charting

This report is an exportable version of the Unfinished Charting in iKnowMed, with additional patient and user details.
Data Last Extracted: 06/14/2026 at 12:00am PST Updates from the last 48 hours may not yet be reflected.

Overview

8
Providers with Unfinished Charting

62
Patients with Unfinished Charting

Breakdown by Item

51
Unfinished Notes

62
Unfinished Pain Care

60
Missing Billing Codes

0
Draft Orders

Unfinished Charting Aging Distribution

62

0

-

ontada[®]
By McKesson

© 2026 Confidential and proprietary

22



WE WANT TO HEAR FROM YOU

Share your feedback on the latest
iKnowMed release

Thursday, July 16, 2026,
at noon CT
during Office Hours

[Sign Up For Office Hours](#)